{"name":"Elpen Pharmaceutical Co. Inc.","slug":"elpen-pharmaceutical-co-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Bosentan group","genericName":"Bosentan group","slug":"bosentan-group","indication":"Pulmonary arterial hypertension","status":"phase_2"}]}],"pipeline":[{"name":"Bosentan group","genericName":"Bosentan group","slug":"bosentan-group","phase":"phase_2","mechanism":"Bosentan is an endothelin receptor antagonist that works by blocking the action of endothelin-1, a potent vasoconstrictor.","indications":["Pulmonary arterial hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE0xUlNVQVExUjE3SU9rdUJIMHl2QXl6Z1V6Qld2REpBd2hoRnN5ZkEzYkUyR2JXSXRENTdvbFVOZlNSYjhLZ1hPbHhhd05Ud1RSRFN2Rm8tMWwwNVJ4SjJvZkllNEdfUEthNU1Rc0FISTRkdDJ5WGtwVjFn?oc=5","date":"2025-10-18","type":"pipeline","source":"Future Market Insights","summary":"Dry Powder Inhaler Market | Global Market Analysis Report - 2035 - Future Market Insights","headline":"Dry Powder Inhaler Market | Global Market Analysis Report - 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOaUpuZS0tVTVZcDlTN0RoZHM0S2cwVlhHSlhXT3pMcC1TWWREM2ZYUlp1eXVPMVNGSmlkcHNza19QcGY1X1FUa2pFTUo3WW5kWDNKYTZPWXo2MW10MWNwck9yLThUSTExYlNyM1QwZEFsNGpiWi1VMXR3QVdPbmhaNUhIbHJMLVRNWTlQNUlfNlo5d0dfYTY5QkEwS2FfNG1zNDNqVDJPMmZRWEgzcF9KT0RIU28ybU1oRXdLQ1dB?oc=5","date":"2023-01-31","type":"patent","source":"JUVE Patent","summary":"Novartis and Freshfields win PIs against eight generics companies in fingolimod battle - JUVE Patent","headline":"Novartis and Freshfields win PIs against eight generics companies in fingolimod battle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPMzBnUEdOZ1h1NVkwcURVZ295WmotTjR4enVQSy1QbzhXanNXN0ZPTnNWcnYyZUgwTXlWalM2a3lUYndZelIzOXZ1RVRJLXpqT25sQ3BtZE1aLWl5MGpSMmp1aElqSzZxNUF4eWpNNm9uN3pHS2x3YVVVZ2ZfVHpZQ2dEaGNac0JZN2RYOWtsS2RRT1VhdDk3UEZyWWJuSmp0MDFJQjJCT0xmc1N2cElOQUNTcHRGMUFqQ2Zhd1hYNDQzd0llWFZNVA?oc=5","date":"2023-01-18","type":"pipeline","source":"thenationalherald.com","summary":"Pharmaceuticals Manufacturer ELPEN to Complete Investments of 155 mln Euros by the End of 2025 - thenationalherald.com","headline":"Pharmaceuticals Manufacturer ELPEN to Complete Investments of 155 mln Euros by the End of 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxONVpWUmJkclkxdmtTU3Jma1ZTWU9xYV9kNzdLZ0wxbXdnaFAyUElZbnJSVGtpOVFxLVI5M0Vzc0pNNUxjdTVzNlhrOGo4ak1vMHBSNld5Q1NCN2FqQXg1UXR6R296M3QxY2hNemZlQjlrXzJhWGRaVDNpcWF5bVFGVG5KTUY5TzZWbWdPd2Q2ZVdRUUYyMGlwRmlpdnF5MUZyMVBXWk80eDZabm9VWkhURW5hUQ?oc=5","date":"2017-10-30","type":"pipeline","source":"Bloomberg.com","summary":"Greece’s Locally Made Drugs May Offer Cure for Excess Spending - Bloomberg.com","headline":"Greece’s Locally Made Drugs May Offer Cure for Excess Spending","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}